What we do Alpa Laboratories Ltd manufactures a broad range of pharmaceutical formulations including ethical, generic, OTC, and veterinary products with various dosage forms such as injectables, tablets, capsules, and ointments. |
Founded in 1,967 |
Market share Established contract manufacturer serving reputed pharma companies nationally and internationally with diverse product portfolio and export footprint in countries across Asia and Africa. |
Problem solved Provides reliable pharmaceutical manufacturing solutions addressing demand for quality formulations across human and veterinary therapies including high-potency and hormonal drugs. |
Top clients or who we serve Serves pharmaceutical companies like Cipla, Zydus Cadila, Lupin, Glenmark and markets products under its own brand to B2B and B2C segments domestically and internationally. |
Key management Mahendra Singh Chawla (Chairman & Whole-Time Director), Paresh Chawla (Managing Director), Pravin Shah (Whole-Time Director), Shitul Shah (Whole-Time Director). |
Our journey and innovations Incorporated 1988, converted to Public Limited in 1998, launched multiple formulations, operationalized new units in 1999 and 2012; acquired subsidiary Norfolk Mercantile Pvt Ltd in 2015; continuous expansion. |
Where we operate Domestic operations primarily in India with exports to Philippines, Iran, Iraq, Sierra Leone, Madagascar, Kenya, Liberia, Puerto Rico, Haiti, Sudan, Ghana, Nigeria, Sri Lanka. |
Top products or what we offer Wide range of injectables (liquid & dry), tablets, capsules, eye/ear drops, ointments, creams, gels, dry syrups, including oral hormonal and high-potency formulations. |
Top brands 'Alpa' trademark for ethical, generic, OTC and veterinary pharmaceutical products; contract manufacturing for marquee pharma companies under their own brands. |
Raw materials needed Pharmaceutical active ingredients, excipients, packaging materials for diverse dosage forms including injectables, tablets, capsules, creams, and dry syrups. |
Raw materials supplier Multiple suppliers in pharmaceutical raw materials sector (specific names not disclosed). |
Recurring vs cyclical contribution Revenue largely recurring from ongoing contract manufacturing and branded pharmaceutical product sales with steady export demand. |
Our industry position Recognized contract manufacturer with diversified dosage capabilities; leading regional presence with established export markets and strong manufacturing infrastructure. |
Financial highlights FY 2024-25 revenues ₹135.76 crores; net profit approximately ₹19.6 crores; growing operational margins and expanding production capacity. |
Geographical revenue split Approximately 70% revenue from domestic Indian market and 30% from international exports. |
Order book - |
Whats driving growth Capacity expansion at Pithampur, growing export markets, increased contract manufacturing volumes, and new product launches. |
Our future plans Expansion at Pithampur manufacturing facility with land acquisition to bolster high potency oral solid dosage capabilities and increase total output. |
Our green promise Focus on safety, environment and health with regular training; comprehensive insurance coverage; compliance with regulatory and sustainability norms. |
Our people and values Diverse, inclusive workforce aligned with core values of courage, accountability, development and teamwork; emphasis on training and talent retention. |
Key challenges ahead Integration of subsidiary merger, scaling high potency manufacturing, regulatory compliance, and competitive pressures in pharma manufacturing. |
Interesting facts One of the earliest pharma firms in Madhya Pradesh with diverse dosage form manufacturing and extensive contract manufacturing collaborations worldwide. |
Risks and strategy Mitigation through internal controls, diversified product/market portfolio, continuous capacity enhancement, adherence to regulatory frameworks, and strong corporate governance. |
